Differentiation of atrial fibroblasts into myofibroblasts plays a critical role in atrial fibrosis. Sodium tanshinone IIA sulfonate (DS‐201), a water‐soluble derivative of tanshinone IIA, has been shown to have potent antifibrotic properties. However, the protective effects of DS‐201 on angiotensin II‐ (Ang II‐) induced differentiation of atrial fibroblasts into myofibroblasts remain to be elucidated. In this study, human atrial fibroblasts were stimulated with Ang II in the presence or absence of DS‐201. Then, α‐smooth muscle actin (α‐SMA), collagen I, and collagen III expression and reactive oxygen species (ROS) generation were measured. The expression of transforming growth factor‐β1 (TGF‐β1) and the downstream signaling of TGF‐β1, such as phosphorylation of Smad2/3, were also determined. The results demonstrated that DS‐201 significantly prevented Ang II‐induced human atrial fibroblast migration and decreased Ang II‐induced α‐SMA, collagen I, and collagen III expression. Furthermore, increased production of ROS and expression of TGF‐β1 stimulated by Ang II were also significantly inhibited by DS‐201. Consistent with these results, DS‐201 significantly inhibited Ang II‐evoked Smad2/3 phosphorylation and periostin expression. These results and the experiments involving N‐acetyl cysteine (antioxidant) and an anti‐TGF‐β1 antibody suggest that DS‐201 prevent Ang II‐induced differentiation of atrial fibroblasts to myofibroblasts, at least in part, through suppressing oxidative stress and inhibiting the activation of TGF‐β1 signaling pathway. All of these data indicate the potential utility of DS‐201 for the treatment of cardiac fibrosis.
Fibrosis is usually the final pathological state of many chronic inflammatory diseases and may lead to organ malfunction. Excessive deposition of extracellular matrix (ECM) molecules is a characteristic of most fibrotic tissues. The blood vessel wall contains three layers of membrane structure, including the intima, which is composed of endothelial cells; the media, which is composed of smooth muscle cells; and the adventitia, which is formed by the interaction of connective tissue and fibroblasts. The occurrence and progression of vascular remodeling are closely associated with cardiovascular diseases, and vascular remodeling can alter the original structure and function of the blood vessel. Dysregulation of the composition of the extracellular matrix in blood vessels leads to the continuous advancement of vascular stiffening and fibrosis. Vascular fibrosis reaction leads to excessive deposition of the extracellular matrix in the vascular adventitia, reduces vessel compliance, and ultimately alters key aspects of vascular biomechanics. The pathogenesis of fibrosis in the vasculature and strategies for its reversal have become interesting and important challenges. Ion channels are widely expressed in the cardiovascular system; they regulate blood pressure, maintain cardiovascular function homeostasis, and play important roles in ion transport, cell differentiation, proliferation. In blood vessels, different types of ion channels in fibroblasts, smooth muscle cells and endothelial cells may be relevant mediators of the development of fibrosis in organs or tissues. This review discusses the known roles of ion channels in vascular fibrosis remodeling and discusses potential therapeutic targets for regulating remodeling and repair after vascular injury.
The PAK (p21-activated kinases) family is a class of intracellular signal transduction protein kinases that regulate various cellular functions, mainly through their interactions with small GTP enzymes. PAK1 and PAK2 in the PAK kinase family are key signal transduction molecules that play important roles in various biological processes, including morphological changes, migration, proliferation, and apoptosis, and are involved in the progression of many diseases. Abnormal expression or dysregulation of PAK1 and PAK2 may be associated with several diseases, including cancer, neurological diseases, etc. The current research mainly focuses on studying the role of PAK and PAK inhibitors in the regulation of cancer progression, but relatively few reports are available that explore their potential role in cardiovascular diseases. Vascular injury and repair are complex processes involved in many cardiovascular conditions, including atherosclerosis, restenosis, and hypertension. Emerging research suggests that PAK1 and PAK2 have pivotal roles in vascular endothelial cell functions, including migration, proliferation, and angiogenesis. These kinases also modulate vascular smooth muscle relaxation, vascular permeability, and structural alterations, which are critical in the development of atherosclerosis and vascular inflammation. By targeting these activities, PAK proteins are essential for both normal vascular physiology and the pathogenesis of vascular diseases, highlighting their potential as therapeutic targets for vascular health. This review focuses on recent studies that offer experimental insights into the mechanisms by which PAK1 and PAK2 regulate the biological processes of vascular injury and repair and the therapeutic potential of the current existing PAK inhibitors in vascular-related diseases. The limitations of treatment with some PAK inhibitors and the ways that future development can overcome these challenges are also discussed.
BACKGROUND: High blood pressure has been suggested to accelerate vascular injury-induced neointimal formation and progression. However, little is known about the intricate relationships between vascular injury and hypertension in the context of arterial remodeling. METHODS: Single-cell RNA-sequencing analysis was used to depict the cell atlas of carotid arteries of Wistar Kyoto rats and spontaneously hypertensive rats with or without balloon injury. RESULTS: We found that hypertension significantly aggravated balloon injury-induced arterial stenosis. A total of 36 202 cells from carotid arteries with or without balloon injury were included in single-cell RNA-sequencing analysis. Cell composition analysis showed that vascular injury and hypertension independently induced distinct aortic cell phenotypic alterations including immune cells, endothelial cells (ECs), and smooth muscle cells. Specifically, our data showed that injury and hypertension-induced specific EC phenotypic alterations, and revealed a transition from functional ECs to hypermetabolic, and eventually dysfunctional ECs in hypertensive rats upon balloon injury. Importantly, our data also showed that vascular injury and hypertension-induced different smooth muscle cell phenotypic alterations, characterized by deferential expression of synthetic signatures. Interestingly, pathway analysis showed that dysregulated metabolic pathways were a common feature in monocytes/macrophages, ECs, and smooth muscle cells in response to injury and hypertension. Functionally, we demonstrate that inhibition of mitochondrial respiration significantly ameliorated injury-induced neointimal formation in spontaneously hypertensive rats. CONCLUSIONS: This study provides the cell landscape changes of the main aortic cell phenotypic alterations in response to injury and hypertension. Our findings suggest that targeting cellular mitochondrial respiration could be a novel therapeutic for patients with hypertension undergoing vascular angioplasty.
BACKGROUND: Mechanisms of endothelial repair in hypertension remain unclear. CD34 + cells are reported to contribute to vascular regeneration; however, their origin and regulation in hypertension are poorly understood. We investigated the role of IK Ca channels in CD34 + cell-mediated endothelial repair during Ang II (angiotensin II)-induced arteriole remodeling. METHODS: Using inducible lineage tracing (Cd34-CreERT2; R26-tdTomato), we tracked nonbone marrow-derived CD34 + cells in hypertensive mice. Single-cell RNA sequencing, immunofluorescence, transwell migration assays, and patch-clamp techniques were used to analyze phenotypic transitions, ion channel activity, and signaling pathways. Bone marrow transplantation, the IK Ca channel inhibitor TRAM-34, and the ERK (extracellular signal-regulated kinase) inhibitor PD98059 were used to validate functional mechanisms. RESULTS: Lineage tracing revealed that nonbone marrow-derived CD34 + cells contributed to endothelial repair under hypertensive conditions. Immunofluorescence analysis showed an increase in CD31 + -tdTomato + cells in the arterioles of Ang II-treated mice after 6 weeks, indicating improved endothelial integrity. Single-cell RNA sequencing revealed 2 subgroups of endothelial cells, one of which expressed stem cell markers such as CD34 (cluster of differentiation 34), Flk-1 (fetal liver kinase 1), and Sca-1 (stem cell antigen-1). Gene expression analysis showed that CD34 + cells are involved in endothelial repair through the regulation of cell migration. Importantly, IK Ca channel activation facilitated CD34 + cell migration, and TRAM-34-based inhibition of IK Ca channels reduced migration. Mechanistic studies revealed that Ang II enhanced CD34 + cell migration via IK Ca -mediated activation of the ERK/P38 signaling pathway, promoting cytoskeletal reorganization and increased intracellular calcium levels. CONCLUSIONS: Arteriole-resident CD34 + cells contribute to endothelial repair in Ang II-induced hypertension. Moreover, IK Ca channel upregulation facilitates CD34 + cell migration via ERK/P38 signaling, suggesting potential therapeutic targets for hypertension.